A first-in-human, phase 1a, dose-escalation study of BGB-10188, a phosphatidylinositol 3-kinase delta (PI3K δ) inhibitor, plus tislelizumab (anti-PD-1) in patients with solid tumors

被引：0
|
作者：
Cosman, Rasha
Ahern, Elizabeth
Li, Jie
Gan, Hui K.
Chen, Yu
Gao, Bo
Wang, Yongsheng
Mu, Xiyan
Cheng, Huan
Qian, Yanrong
Zhang, Heather
Cao, Ke
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT189
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT189
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours
    Alison M. Schram
    Leena Gandhi
    Monica M. Mita
    Lars Damstrup
    Frank Campana
    Manuel Hidalgo
    Enrique Grande
    David M. Hyman
    Rebecca S. Heist
    [J]. British Journal of Cancer, 2018, 119 : 1471 - 1476
  • [42] First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas
    Piha-Paul, Sarina A.
    Geva, Ravit
    Tan, Tira J.
    Lim, Darren Wt
    Hierro, Cinta
    Doi, Toshikiko
    Rahma, Osama
    Lesokhin, Alexander
    Luke, Jason John
    Otero, Javier
    Nardi, Lisa
    Singh, Angad
    Xyrafas, Alexandros
    Chen, Xinhui
    Mataraza, Jennifer
    Bedard, Philippe L.
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (08)
  • [43] First-in-Human Trial of the PI3Kβ-Selective Inhibitor SAR260301 in Patients With Advanced Solid Tumors
    Bedard, Philippe L.
    Davies, Michael A.
    Kopetz, Scott
    Juric, Dejan
    Shapiro, Geoffrey I.
    Luke, Jason J.
    Spreafico, Anna
    Wu, Bin
    Castell, Christelle
    Gomez, Corinne
    Cartot-Cotton, Sylvaine
    Mazuir, Florent
    Dubar, Michel
    Micallef, Sandrine
    Demers, Brigitte
    Flaherty, Keith T.
    [J]. CANCER, 2018, 124 (02) : 315 - 324
  • [44] Phase I Dose-Escalation Study of the Dual PI3K-mTORC1/2 Inhibitor Gedatolisib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors
    Colombo, Ilaria
    Genta, Sofia
    Martorana, Federica
    Guidi, Monia
    Frattini, Milo
    Samartzis, Eleftherios Pierre
    Brandt, Simone
    Gaggetta, Sheila
    Moser, Laura
    Pascale, Mariarosa
    Terrot, Tatiana
    Sessa, Cristiana
    Stathis, Anastasios
    [J]. CLINICAL CANCER RESEARCH, 2021, 27 (18) : 5012 - 5019
  • [45] A phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors
    Desai, Jayesh
    Davar, Diwakar
    Deva, Sanjeev
    Gao, Bo
    Liu, Tianshu
    Matos, Marco
    Meniawy, Tarek
    O'Byrne, Kenneth John
    Sun, Meili
    Voskoboynik, Mark
    Yang, Kunyu
    Yu, Xinmin
    Chen, Xin
    Dong, Yan
    Giovinazzo, Hugh
    Leaw, Shiangjiin
    Patel, Deepa
    Rahman, Tahmina
    Wu, Yanjie
    Day, Daphne
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] A first-in-human, phase 1a/1b, open-label, dose-escalation and expansion study to investigate the safety, pharmacokinetics, and antitumor activity of the RAF dimer inhibitor BGB-3245 in patients with advanced or refractory tumors
    Schram, Alison M.
    Subbiah, Vivek
    Sullivan, Ryan
    Cosman, Rasha
    Liu, Jia
    Sbar, Eric I.
    Thuy Hoang
    Chen, Jiarong
    Johnson, Mark
    Amoruccio, Vincent
    Shearer, Todd
    Kamal, Adeela
    Lewis, Jocelyn
    Shao, Wenlin
    Edris, Badreddin
    Luo, Lusong
    Desai, Jayesh
    [J]. CANCER RESEARCH, 2023, 83 (08)
  • [47] First-in-human (FIH), pharmacokinetic (PK) and pharmacodynamic (PD) study of IOA-244, a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in patients with advanced metastatic mesothelioma, uveal and cutaneous melanoma
    Di Giacomo, A. M.
    Santangelo, F.
    Amato, G.
    Simonetti, E.
    Graham, J.
    Lahn, M.
    Zorilla, R.
    van der Veen, L.
    Johnson, Z.
    Pickering, C.
    Marechal, E.
    Blanco, J.
    Blanco, J.
    Durini, M.
    Gufford, B.
    Lakshmikanth, T.
    Brodin, P.
    Spiliopoulou, P.
    Evans, T. R. J.
    Maio, M.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1438 - S1438
  • [48] First-in-human phase 1 dose-escalation study of DS-6051b, an oral ROS1 and NTRK inhibitor, in subjects with advanced solid tumors
    Papadopoulos, Kyriakos P.
    Borazanci, Erkut
    Von Hoff, Daniel
    Gandhi, Leena
    Patnaik, Amita
    Tachibana, Masaya
    Zahir, Hamim
    Gajee, Roohi
    Goldberg, Tern
    Senaldi, Giorgio
    Ou, Sai-Hong
    [J]. CANCER RESEARCH, 2016, 76
  • [49] First-in-human study of HMPL-295, an ERK1/2 inhibitor, in patients with advanced solid tumors: Dose-escalation results of monotherapy
    Yu, Xianjun
    Zhang, Jian
    Sun, Yuping
    Deng, Yanhong
    Guo, Shuangshuang
    Hong, Wei
    Shi, Si
    Liu, Rujiao
    Gao, Shuiping
    Dang, Qi
    Zhang, Jianwei
    Su, Weiguo
    Shi, Michael
    Fan, Songhua
    Zhang, Bo
    Pan, Beiqing
    Jia, Xiaoyun
    Wang, Jian
    Zhong, Chen
    Ma, Luguang
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [50] First-in-human Phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors.
    Hollebecque, Antoine
    Soria, Jean-Charles
    Bahleda, Ratislav
    Lopez-Busto, Natividad
    Jacquet-Bescond, Anne
    Burbridge, Mike F.
    Valerie, Cattan
    Pauly, Jeanne
    Herranz, Maria
    Azaro, Analia
    Depil, Stephane
    Rodon, Jordi
    [J]. MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
12345